BG
Last reporting period 30 Sep, 2023
Updated 18 Sep, 2024
Last price
—
Market cap $B
0.008
Exchange
XNAS - Nasdaq
-0.0009 B
Last period CFO ,USD
What is CFO ?
Operating cash flow is the difference between the income and expenses of cash that is generated as a result of the main activities of the company.
See also BioNexus Gene
Company Analysis
BGLC valuation, rating, competitors, insights and company profile
Eyestock Rating
BGLC financial analysis by Eyestock methodology
Valuation
BGLC valuation using historical relative method
Statements
BGLC Income Statements, Balance Sheet and Cash Flow Statements
Dividends
BGLC dividend yield and annual dividend
Operating cash flow is the difference between the income and expenses of cash that is generated as a result of the main activities of the company.
BioNexus Gene`s CFO for the period ended 2023-09-30 is -0.0009 B USD
